Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Debt Repayments (2018 - 2024)

Zevra Therapeutics (ZVRA) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $42.7 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Long-Term Debt Repayments rose 20528.02% year-over-year to $42.7 million, compared with a TTM value of $42.7 million through Sep 2025, down 9.97%, and an annual FY2024 reading of $42.7 million, up 143.57% over the prior year.
  • Long-Term Debt Repayments was $42.7 million for Q2 2024 at Zevra Therapeutics, up from $4.7 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $42.7 million in Q2 2024 and bottomed at -$207000.0 in Q3 2023.
  • Average Long-Term Debt Repayments over 3 years is $16.4 million, with a median of $8.8 million recorded in 2023.
  • Peak annual rise in Long-Term Debt Repayments hit 20528.02% in 2024, while the deepest fall reached 20528.02% in 2024.
  • Year by year, Long-Term Debt Repayments stood at $37.9 million in 2021, then plummeted by 87.53% to $4.7 million in 2023, then skyrocketed by 802.56% to $42.7 million in 2024.
  • Business Quant data shows Long-Term Debt Repayments for ZVRA at $42.7 million in Q2 2024, $4.7 million in Q4 2023, and -$207000.0 in Q3 2023.